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Abstract  
In the UK it is estimated the NHS spends almost 
£100 million every year in unused drugs. In 
addition, hospital admission costs attributed to 
patients not taking their prescribed medicine 
properly was estimated to be between £36m and 
£197m per year. In the U.S., medication non-
adherence is estimated to lead to between $100 and 
$300 billion of avoidable healthcare costs annually, 
representing 3–10% of total U.S. healthcare costs. 
Studies show that improving medication adherence 
may have a greater influence on the health of the 
population than the discovery of any new therapy. 
Effective medicines are available for many 
conditions and yet patients are non-adherent 50% 
of the time. This can be critical point in certain 
disease states, such as asymptomatic conditions like 
hypertension, where the incidence may approach 
80% non-compliance. It is proposed to create a 
therapeutic adherence monitoring device within a 
smart blister pack that is coupled to a device with 
the capacity to collect and send data to a common 
server. This would allow a clinician to know, with 
high certainty, if the patient is taking their 
medication as prescribed and on schedule. This 
paper gathers information to identify current 
technology to support integrated monitoring and 
control of therapeutic adherence. 
 
Keywords:  non-adherence; portable devices; Internet 
of Things; telemonitoring  
 
Introduction  
   
The World Health Organization (WHO) estimated 
that, in 2001, chronic diseases contributed to 
approximately 60% of the 56.5 million total reported 
deaths in the world, and approximately 46% of the 
global burden of disease. In 2020 this is expected to 
increase to 57%.1 
In Portugal, 5.4 million people live with one or  
 
more chronic conditions. Additionally, Portuguese 
women over 65 years have only 6.6 years of healthy 
life remaining. In contrast, Norwegian women have, 
on average, have 15.4 years of healthy life remaining. 
Other countries share this trend, and the increased 
incidence of chronic disease must be seen as a wake-
up call to health services worldwide.2 
Improving medication adherence may have a 
greater influence on the health of the population than 
the discovery of any new therapy. Effective medicines 
are available for many conditions and yet patients are 
non-adherent to their medication 50% of the time.3 
Studies report different ranges of adherence - for adult 
patients 40–60%, and for children 25–75%, but on 
average only 50% of people take their medicines 
properly.4 This has become critical for some 
asymptomatic diseases such as hypertension, where 
non-compliance may approach 80%.5 
Patient adherence to prescribed medication 
regimens is a complex and multidimensional 
behaviour, and to understand what is happening the 
problem must be dissected to identify modifiable 
factors. To achieve this the reasons for intentional and 
non-intentional non-adherence must be understood. 
These have been classified into patient factors, 
medication factors, health care provider factors, health 
care system factors, and socioeconomic factors.  
Economic and Health Cost of Non-adherence 
In the UK, it’s estimated that the National Health 
System (NHS) spends nearly $11 billion each year on 
medicines, issuing 927 million prescriptions. More 
than $121 million constitutes unused and returned 
drugs, which are destroyed. In addition, hospital 
admission costs attributed to patients not taking their 
prescribed medicine properly was estimated at 
between $44-$240 million per year.4 
In the United States of America (USA), medication 
non-adherence leads to between $100 and $300 Billion 
of avoidable healthcare costs annually, or about 3–
10% of total USA healthcare costs. Health-related lost 
productivity costs are 2.3 times higher than the direct 
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healthcare costs. In contrast, medication adherence in 
patients with one or more chronic vascular conditions 
resulted in a reduction of average annual medical 
spending by $8,881 in congestive heart failure, $4,337 
in hypertension, and $4,413 in diabetes. Further, it is 
estimated that improved adherence to diabetes 
medication could avert 699,000 emergency department 
visits and 341,000 hospitalisations annually, 
amounting to a savings of $4.7 billion.3 
 A recent National Institute for Health Care 
Management (NIHCM) foundation data brief 
concluded that the top 1% healthcare spenders in the 
USA account for more than 20% of the spending, and 
that the top 5% account for almost 50% of all allocated 
health resources. Investigating the common conditions 
of these patients revealed the top five to be 
uncontrolled hypertension, dyslipidaemia and diabetes 
mellitus – some of the diseases with the lowest 
adherence rates.6 
Potential health losses must be considered also. 
Therapeutic non-adherence becomes a problem when 
the only way to prevent certain diseases is by taking 
prescribed medications. A lack of awareness and 
motivation for some patients, and for some health 
problems such as hypertension and high LDL 
cholesterol (dyslipidaemia), results in inconsistent and 
inadequate medication intake. In the worst case, 
complete neglect of prescribed medication usage, the 
danger may not be appreciated by patients.  
As an example, in the case of arterial hypertension 
a population-based study concluded that non-
adherence to antihypertensive medication was 
associated with a 5.7-fold increase in the odds of a 
fatal stroke during the year of death, and a 2-fold 
increased risk of non-fatal stroke.7 Stroke, only one of 
hypertension’s related complications, causes 11% of 
all deaths worldwide and is the second most common 
cause of death after ischemic heart disease8 with, in 
2010, stroke-related disability being the third most 
common cause of reduced disability-adjusted life-
years.9  
Solutions 
Each disease has its own special challenges, and 
causes of the behaviour must be understood. Many 
conditions may be aggravated or even fatal without the 
correct intervention, and it must be assumed that non-
adherence cuts across all medical specialties. 
The growth in technological solutions has resulted 
in many gadgets and devices becoming available for 
practically everything. Some could make a difference 
with medication adherence. It is important to know 
“the state of the art” of medication adherence devices, 
particularly portable ones that function regardless of 
the location of intake. This is an area with relatively 
few published articles, and a need for additional 
research. Furthermore, available systematic reviews 
reveal small sample sizes and make the conclusions 
questionable. Also, there is a lack of real-life usage of 
these technologies since the main market for these 
devices are clinical drug trials. 
For this report two systematic reviews were 
examined. In the first the authors considered that, 
although positive effects on adherence were reported, 
rigorously conducted studies are needed to inform the 
use of electronic multi-compartment medical 
devices.10 The second systematic review addressed 
simple devices that monitor and store adherence 
records, and devices that combine digital displays with 
audible reminder alarms. Of these, electronic 
medication packaging (EMP) devices appeared most 
useful for improving adherence, with  1 to 34% of 
increased adherence, depending on the kind of 
intervention.11 At this time it is almost impossible to 
establish, with a high degree of certainty, the 
importance of monitoring devices in clinical practice, 
and its impact on the problem of non-adherence. 
However, with growth of the Internet of Things 
(IoT) and combination with medication adherence 
technology, circumstances may change. Healthcare 
today relies on analytic data for almost everything. Yet 
for medication adherence the only input, besides 
analytic control by blood sampling, is the patient-
reported data on medication intake. Future 
technological devices that fit within the lifestyle of the 
average person could be a game-changer in therapeutic 
non-adherence. 
Sensor technology is making the creation of new 
data much easier. But to be useful, those data need to 
be communicated, aggregated, and analysed in ways 
that enable new and more effective action. Several 
IoT-enabled devices are available to patients and 
providers to monitor diabetes, heart conditions, and 
other ailments. However, the devices are rarely set up 
to export their data to a system that aggregates and 
shares information with all involved (clinicians and 
patients). 
Therefore the real goal is to interconnect all 
ambulatory devices to send information to an IoT-
based system that allows real-time monitoring by 
health professionals of patient’s biosignals and 
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adherence behaviour. Such a tool would provide 
feedback to patients helping them engage and make 
better health and wellness decisions in real-time, 
decreasing the need for costly clinician visits, tests, 
and hospitalisations, and reducing the rate of 




Therapeutic non-adherence is a public health problem 
that leads to high economic and health losses. Raised 
awareness amongst health professionals and the 
general population is needed. As shown above, 
currently it is impossible to determine the real impact 
of portable monitoring devices in therapeutic non-
adherence in day-to-day clinical practice. A proposed 
solution is to create a therapeutic adherence 
monitoring device contained in a smart blister pack, 
that is coupled to a device which has the capacity to 
collect (from other medical devices) and send data 
(medicine time of ingestion, blood pressure and 
oximetry) to a common server with a real-time 
monitoring system. This will allow a clinician to 
know, with high certainty, if the patient is taking their 
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